HOLX - Hologic Inc Stock Price, Fair Value and News

75.86USD-0.24 (-0.32%)Market Closed

Market Summary

USD75.86-0.24

Market Closed

-0.32%

HOLX Stock Price

View Fullscreen

HOLX RSI Chart

HOLX Valuation

Market Cap

17.7B

Price/Earnings (Trailing)

37.95

Price/Sales (Trailing)

4.47

EV/EBITDA

23.39

Price/Free Cashflow

16.04

HOLX Price/Sales (Trailing)

HOLX Profitability

EBT Margin

14.15%

Return on Equity

9.63%

Return on Assets

5.35%

Free Cashflow Yield

6.24%

HOLX Fundamentals

HOLX Revenue

Revenue (TTM)

4.0B

Rev. Growth (Yr)

-0.85%

Rev. Growth (Qtr)

0.46%

HOLX Earnings

Earnings (TTM)

466.5M

Earnings Growth (Yr)

-22.24%

Earnings Growth (Qtr)

-31.08%

Breaking Down HOLX Revenue

Last 7 days

-0.5%

Last 30 days

-2.0%

Last 90 days

3.3%

Trailing 12 Months

-9.3%

How does HOLX drawdown profile look like?

HOLX Financial Health

Current Ratio

3.97

Debt/Equity

0.52

Debt/Cashflow

0.44

HOLX Investor Care

Buy Backs (1Y)

5.18%

Diluted EPS (TTM)

1.96

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	4.0B	0	0	0
2023	4.1B	4.0B	4.0B	4.0B
2022	5.4B	5.2B	4.9B	4.5B
2021	5.3B	5.7B	5.6B	5.5B
2020	3.3B	3.3B	3.8B	4.5B
2019	3.3B	3.3B	3.4B	3.4B
2018	2.1B	2.8B	3.2B	3.3B
2017	2.9B	2.3B	2.0B	2.1B
2016	2.8B	2.8B	2.8B	0
2015	2.6B	2.7B	2.7B	2.7B
2014	2.5B	2.5B	2.5B	2.6B
2013	2.3B	2.5B	2.5B	2.5B
2012	1.9B	1.9B	2.0B	2.2B
2011	1.1B	1.5B	1.8B	1.8B
2010	1.4B	1.1B	819.1M	839.2M
2009	1.7B	1.6B	1.6B	1.6B
2008	0	1.2B	1.7B	1.7B
2007	0	0	738.4M	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Hologic Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 22, 2024	macmillan stephen p	gifted	-	-	-12,000	chairman, president and ceo
Apr 19, 2024	macmillan stephen p	gifted	-	-	-12,000	chairman, president and ceo
Mar 14, 2024	garrett scott t	acquired	508,471	30.927	16,441	-
Mar 14, 2024	garrett scott t	sold	-1,241,300	75.5	-16,441	-
Mar 08, 2024	crawford sally	acquired	241,703	26.74	9,039	-
Mar 08, 2024	crawford sally	sold	-690,607	76.403	-9,039	-
Mar 08, 2024	dockendorff charles j	sold	-111,648	76.21	-1,465	-
Mar 07, 2024	crawford sally	acquired	-	-	1,572	-
Mar 07, 2024	hantson ludwig	acquired	-	-	1,572	-
Mar 07, 2024	mohtashami nanaz	acquired	-	-	1,572	-

Which funds bought or sold HOLX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	OPPENHEIMER ASSET MANAGEMENT INC.	added	14.94	545,711	2,693,280	0.04%
May 07, 2024	QRG CAPITAL MANAGEMENT, INC.	reduced	-50.96	-5,170,190	5,949,680	0.08%
May 07, 2024	Smithfield Trust Co	added	15.6	5,000	22,000	-%
May 07, 2024	Headlands Technologies LLC	reduced	-83.21	-1,058,570	237,466	0.06%
May 07, 2024	OPPENHEIMER & CO INC	added	3.94	182,323	1,541,660	0.03%
May 07, 2024	SEI INVESTMENTS CO	added	8.8	17,481,600	110,901,000	0.16%
May 07, 2024	Empirical Financial Services, LLC d.b.a. Empirical Wealth Management	added	15.24	831,780	4,062,960	0.12%
May 07, 2024	PANAGORA ASSET MANAGEMENT INC	added	12.01	17,562,800	96,632,500	0.50%
May 07, 2024	NUANCE INVESTMENTS, LLC	added	94.62	27,447,400	51,878,200	1.36%
May 07, 2024	WestEnd Advisors, LLC	unchanged	-	26.00	312	-%

Are Funds Buying or Selling HOLX?

Are funds buying HOLX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HOLX

No. of Funds

Unveiling Hologic Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	t. rowe price investment management, inc.	9.2%	22,071,713	SC 13G
Feb 13, 2024	vanguard group inc	11.53%	27,678,976	SC 13G/A
Jan 08, 2024	blackrock inc.	10.1%	24,263,694	SC 13G/A
Feb 14, 2023	t. rowe price investment management, inc.	9.5%	23,376,904	SC 13G
Feb 09, 2023	vanguard group inc	11.60%	28,519,496	SC 13G/A
Jan 24, 2023	blackrock inc.	9.6%	23,478,641	SC 13G/A
Feb 14, 2022	price t rowe associates inc /md/	16.4%	41,296,661	SC 13G/A
Feb 10, 2022	vanguard group inc	10.94%	27,500,693	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Feb 01, 2022	blackrock inc.	8.7%	21,888,278	SC 13G/A

Recent SEC filings of Hologic Inc

View All Filings

Date Filed	Form Type	Document
May 03, 2024	10-Q	Quarterly Report
May 03, 2024	8-K/A	Current Report
May 02, 2024	8-K	Current Report
Apr 23, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 14, 2024	144	Notice of Insider Sale Intent
Mar 12, 2024	8-K	Current Report
Mar 11, 2024	4	Insider Trading
Mar 11, 2024	4	Insider Trading
Mar 11, 2024	4	Insider Trading

Peers (Alternatives to Hologic Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.6B	40.3B	-5.05%	-4.82%	32.45	4.53	-2.84%	-3.08%
BDX	67.4B	19.7B	-3.45%	-6.52%	50.6	3.42	4.82%	-17.56%
ALGN	20.6B	3.9B	-14.54%	-9.65%	44.54	5.26	5.72%	46.72%
BAX	18.2B	14.9B	-15.38%	-17.01%	6.88	1.22	2.98%	207.68%
MID-CAP
ATR	10.0B	3.5B	7.32%	25.05%	31.94	2.82	6.16%	35.06%
HSIC	9.3B	12.5B	0.39%	-2.78%	24.01	0.75	-0.61%	-18.83%
BIO	7.6B	2.6B	-17.82%	-26.90%	-23.72	2.94	-6.25%	-68.62%
XRAY	5.8B	3.9B	-13.74%	-32.04%	-61.76	1.47	0.23%	91.03%
AXNX	3.4B	387.1M	-0.59%	20.47%	-215.56	8.87	30.82%	65.57%
PDCO	2.3B	6.6B	-1.26%	-0.69%	11.98	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.92%	-14.34%	-1.85	0.4	7.94%	-1661.78%
ANIK	423.5M	169.3M	11.74%	12.93%	-5.51	2.5	7.49%	-244.90%
ANGO	236.7M	324.0M	-10.59%	-34.33%	-1.23	0.73	-3.19%	-337.41%
APYX	45.4M	52.3M	-10.27%	-60.90%	-2.43	0.87	17.61%	19.28%
AEMD	3.3M	3.7M	-25.00%	250.00%	-0.27	0.88	5.77%	8.23%

Hologic Inc News

Latest updates

Hologic Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	0.5%	1,018	1,013	945	984	1,027	1,074	953	1,003	1,436	1,471	1,317	1,168	1,538	1,610	1,347	823	756	851	866	852	818
Gross Profit	-4.4%	542	568	500	368	586	618	515	550	947	986	828	702	1,086	1,180	932	466	396	434	250	445	42.00
Operating Expenses	-10.1%	332	369	368	366	314	356	374	286	353	345	389	343	289	295	299	275	239	309	336	300	366
S&GA Expenses	-3.2%	144	149	140	150	142	164	159	152	171	147	159	143	132	128	126	104	111	145	142	144	134
R&D Expenses	11.7%	75.00	67.00	73.00	73.00	74.00	75.00	76.00	65.00	70.00	73.00	77.00	69.00	72.00	59.00	57.00	55.00	49.00	61.00	60.00	61.00	57.00
EBITDA Margin	-7.3%	0.19*	0.21*	0.22*	0.22*	0.27*	0.31*	0.36*	0.39*	0.39*	0.42*	0.45*	0.49*	-	-	-	-	-	-	-	-	-
Interest Expenses	24.2%	32.00	26.00	28.00	28.00	27.00	28.00	24.00	23.00	23.00	26.00	23.00	22.00	21.00	28.00	25.00	27.00	31.00	33.00	35.00	35.00	35.00
Income Taxes	175.4%	42.00	-55.20	55.00	53.00	61.00	52.00	25.00	20.00	119	123	82.00	69.00	161	179	124	32.00	24.00	-288	1.00	20.00	-81.10
Earnings Before Taxes	10.6%	212	191	146	12.00	279	239	143	248	574	622	411	338	781	832	617	168	119	97.00	-122	114	-353
EBT Margin	-10.6%	0.14*	0.16*	0.17*	0.17*	0.22*	0.27*	0.33*	0.36*	0.36*	0.39*	0.42*	0.45*	-	-	-	-	-	-	-	-	-
Net Income	-31.1%	170	247	91.00	-40.50	219	187	119	228	456	499	329	268	619	653	494	136	95.00	386	-123	94.00	-272
Net Income Margin	-9.2%	0.12*	0.13*	0.11*	0.12*	0.19*	0.22*	0.27*	0.29*	0.29*	0.31*	0.33*	0.36*	-	-	-	-	-	-	-	-	-
Free Cashflow	32.9%	292	220	212	286	159	206	122	284	1,015	517	418	643	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	2.9%	8,714	8,470	9,139	9,338	9,449	9,290	9,071	9,357	9,515	9,285	8,920	8,591	8,044	7,551	7,196	6,803	6,822	6,312	6,442	6,522	6,525
Current Assets	8.4%	3,789	3,494	4,185	4,339	4,211	4,021	3,862	3,909	3,881	3,506	3,169	2,418	2,662	2,596	2,222	1,983	1,937	1,638	1,793	1,592	1,511
Cash Equivalents	12.8%	2,180	1,932	2,723	2,765	2,582	2,441	2,340	2,375	2,291	1,421	1,170	828	816	869	701	744	800	382	602	428	401
Inventory	2.5%	649	634	618	680	688	678	624	581	526	518	501	503	456	420	395	414	401	381	445	468	443
Net PPE	-0.4%	525	527	517	493	498	494	482	490	507	554	565	551	534	515	492	456	445	452	471	470	470
Goodwill	-0.4%	3,292	3,306	3,281	3,298	3,297	3,290	3,237	3,286	3,317	3,329	3,282	428	2,857	32.00	2,658	2,593	2,592	2,594	2,564	-	-
Current Liabilities	6.2%	955	899	1,207	981	955	956	938	1,001	1,305	1,279	1,327	1,465	1,036	1,056	1,239	1,346	1,481	1,043	1,070	1,015	1,045
Long Term Debt	-0.3%	2,514	2,523	2,531	2,789	2,798	2,806	2,808	2,815	2,813	2,820	2,712	2,655	2,672	2,690	2,714	2,731	2,749	2,769	2,784	2,792	2,800
LT Debt, Current	0%	37.00	37.00	287	32.00	26.00	21.00	15.00	8.00	256	249	313	461	75.00	75.00	325	566	750	302	271	234	311
LT Debt, Non Current	-100.0%	-	2,523	2,531	2,789	2,798	2,806	2,808	2,815	2,813	2,820	2,712	2,655	2,672	2,690	2,714	2,731	2,749	2,769	2,784	2,792	2,800
Shareholder's Equity	4.1%	4,844	4,654	5,017	5,182	5,301	5,093	4,876	4,998	4,793	4,519	4,219	3,877	3,795	3,269	2,707	2,259	2,091	2,258	2,116	2,217	2,160
Retained Earnings	7.4%	2,473	2,303	2,056	1,966	2,006	1,788	1,600	1,482	1,253	798	298	-30.50	-298	-918	-1,573	-2,068	-2,206	-2,302	-2,688	-2,565	-2,659
Additional Paid-In Capital	2.3%	6,198	6,059	6,141	6,123	6,092	6,061	6,043	6,017	5,997	5,964	5,966	5,936	5,927	5,895	5,905	5,862	5,828	5,750	5,770	5,739	5,723
Accumulated Depreciation	-	734	-	714	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	-1.1%	236	239	247	247	248	247	252	252	252	253	257	256	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	2.00	4.00	5.00	7.00	-	-	-
Float	-	-	-	-	-	19,638	-	-	-	18,758	-	-	-	18,639	-	-	-	8,530	-	-	-	12,895

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	32.9%	292	220	259	333	206	253	169	331	1,062	564	465	663	552	650	442	223	118	114	248	164	134
Share Based Compensation	-10.1%	26.00	29.00	19.00	17.00	23.00	21.00	15.00	15.00	18.00	19.00	14.00	15.00	17.00	19.00	30.00	20.00	16.00	18.00	14.00	14.00	18.00
Cashflow From Investing	63.1%	-38.50	-104	-56.00	-38.70	-16.40	-41.00	-32.10	-9.80	9.00	-173	-43.10	-758	-478	-49.90	-137	-36.30	78.00	-45.70	-80.80	-32.80	-36.40
Cashflow From Financing	99.6%	-4.20	-943	-210	-109	-49.50	-113	-169	-240	-202	-143	-82.00	110	-129	-428	-350	-241	223	-289	9.00	-104	-8.00
Buy Backs	-100.0%	-	677	211	114	50.00	100	175	-	200	167	0.00	188	120	101	100	-0.10	268	286	-	50.00	3.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

HOLX Income Statement

2024-03-30

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Millions	3 Months Ended		6 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Mar. 30, 2024	Apr. 01, 2023
Revenues:
Product	$ 828.0	$ 837.4	$ 1,656.0	$ 1,723.8
Service and other	189.8	189.1	374.9	376.9
Revenues	1,017.8	1,026.5	2,030.9	2,100.7
Costs of revenues:
Product	308.6	292.1	615.7	588.3
Amortization, Cost of Goods Sold	44.9	52.1	90.5	107.7
Impairment of intangible asset	25.9	0.0	25.9	0.0
Service and other	96.1	96.5	189.0	201.0
Gross profit	542.3	585.8	1,109.8	1,203.7
Operating expenses:
Research and development	74.6	74.0	141.4	148.8
Selling and marketing	144.2	142.4	293.1	305.9
General and administrative	100.4	100.8	212.2	209.3
Amortization of acquired intangible assets	5.7	7.1	19.0	14.7
Impairment of intangible assets	0.9	0.0	5.2	0.0
Contingent consideration - fair value adjustments	0.0	(12.4)	1.7	(12.4)
Restructuring charges	6.1	1.8	28.6	2.9
Operating expenses	331.9	313.7	701.2	669.2
Income from operations	210.4	272.1	408.6	534.5
Interest income	24.0	31.5	51.9	52.1
Interest expense	(32.3)	(27.2)	(58.3)	(55.3)
Other income (expense), net	9.4	2.9	0.6	(12.9)
Income before income taxes	211.5	279.3	402.8	518.4
Provision (benefit) for income taxes	41.6	60.8	(13.6)	112.5
Net income	$ 169.9	$ 218.5	$ 416.4	$ 405.9
Net income per common share:
Basic (in usd per share)	$ 0.72	$ 0.88	$ 1.76	$ 1.64
Diluted (in usd per share)	$ 0.72	$ 0.87	$ 1.74	$ 1.63
Weighted average number of shares outstanding:
Basic (in shares)	235,890	247,730	237,258	247,524
Diluted (in shares)	237,562	249,793	238,888	249,537

HOLX Balance Sheet

2024-03-30

Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 30, 2024	Sep. 30, 2023
Current assets:
Cash and cash equivalents	$ 2,180.0	$ 2,722.5
Accounts receivable, less reserves	647.1	625.6
Inventory	649.2	617.6
Prepaid Expense, Current	165.5	175.3
Prepaid Income Taxes-Current	146.9	31.6
Disposal Group, Including Discontinued Operation, Assets	0.0	11.9
Total current assets	3,788.7	4,184.5
Property, plant and equipment, net	524.8	517.0
Intangible assets, net	751.9	888.6
Goodwill	3,292.4	3,281.3
Other assets	356.6	267.9
Total assets	8,714.4	9,139.3
Current liabilities:
Current portion of long-term debt	37.4	287.0
Accounts payable	202.5	175.2
Accrued expenses	503.5	534.6
Deferred revenue	208.0	199.2
Finance lease obligations	3.2	3.1
Disposal Group, Including Discontinued Operation, Liabilities, Current	0.0	8.2
Total current liabilities	954.6	1,207.3
Long-term debt, net of current portion	2,514.1	2,531.2
Finance lease obligations, net of current portion	13.8	15.3
Deferred Income Tax Liabilities, Net	18.4	20.2
Deferred revenue, net of current portion	14.8	13.8
Other long-term liabilities	354.3	334.6
Stockholders’ equity:
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued	0.0	0.0
Common stock, $0.01 par value – 750,000 shares authorized; 300,756 and 299,940 shares issued, respectively	3.0	3.0
Additional paid-in-capital	6,197.6	6,141.2
Retained earnings	2,472.7	2,056.3
Treasury stock, at cost – 67,380 and 58,231 shares, respectively	(3,691.9)	(3,036.0)
Accumulated other comprehensive loss	(137.0)	(147.6)
Total stockholders’ equity	4,844.4	5,016.9
Total liabilities and stockholders’ equity	$ 8,714.4	$ 9,139.3

About Hologic Inc

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalovirus; Aptima BV and Aptima CV/TV assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. It also offers solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology, and treatment, such as 2D and 3D digital mammography systems, image analytics software, reading workstations, ultrasound imaging, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and ultrasound and connectivity solutions, as well as breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology in the uterus; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; and the CoolSeal portfolio that includes bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

CEO	Mr. Stephen P. MacMillan
WEBSITE	hologic.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	6944

Hologic Inc Frequently Asked Questions

What is the ticker symbol for Hologic Inc? What does HOLX stand for in stocks?

HOLX is the stock ticker symbol of Hologic Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Hologic Inc (HOLX)?

As of Wed May 08 2024, market cap of Hologic Inc is 17.7 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HOLX stock?

You can check HOLX's fair value in chart for subscribers.

What is the fair value of HOLX stock?

You can check HOLX's fair value in chart for subscribers. The fair value of Hologic Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Hologic Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HOLX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Hologic Inc a good stock to buy?

The fair value guage provides a quick view whether HOLX is over valued or under valued. Whether Hologic Inc is cheap or expensive depends on the assumptions which impact Hologic Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HOLX.

What is Hologic Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, HOLX's PE ratio (Price to Earnings) is 37.95 and Price to Sales (PS) ratio is 4.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HOLX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Hologic Inc's stock?

In the past 10 years, Hologic Inc has provided 0.12 (multiply by 100 for percentage) rate of return.